Tucidinostat
Lymphoma, Extranodal NK-T-Cell
Huiqiang HuangSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Lymphoma, Extranodal NK-T-Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide International Extranodal Lymphoma Study Group (IELSG) | Phase 3 | BB |
PREDNISONE TABLETS Sun Yat-sen University | Phase 3 | BB |
Eloxatin Sun Yat-sen University | Phase 3 | BB |
ETOPOSIDE Sichuan University | Phase 3 | BB |
Inno-206 Sun Yat-sen University | Phase 3 | BB |
View all 24 →
Same molecule, other indications
Tucidinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →